This company has been marked as potentially delisted and may not be actively trading. NASDAQ:VSAR Versartis (VSAR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Versartis Stock (NASDAQ:VSAR) 30 days 90 days 365 days Advanced Chart Get Versartis alerts:Sign Up Key Stats Today's Range$1.18▼$1.3050-Day Range$1.19▼$1.1952-Week Range$1.14▼$2.76Volume349,963 shsAverage Volume479,436 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.Read More… Receive VSAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Versartis and its competitors with MarketBeat's FREE daily newsletter. Email Address VSAR Stock News Headlines16 Biopharma Companies Besides Medivation That Are Attractive TargetsJuly 21, 2023 | thestreet.comDon't Tell Anyone: Insiders Are Buying These Stocks Like CrazyDecember 28, 2022 | thestreet.comMemorial Day Sale! 82% Off Disruptors and Dominators!Jensen Huang recently gave the keynote speech at the Consumer Electronics Show in Las Vegas. When the Nvidia CEO walked on stage, you could've heard a pin drop. Why? Robots — built by Nvidia.May 24, 2025 | Weiss Ratings (Ad)Zluri Hires Todd Dekkinga as Chief Information Security Officer - Yahoo FinanceOctober 11, 2022 | finance.yahoo.comAscendis Pharma: Biotech Bear Provides Attractive Entry Point - Seeking AlphaMay 9, 2022 | seekingalpha.comVersartis Price Gains on Drug Approval, eHealth Rises: Tech Winners & LosersMarch 21, 2022 | thestreet.comAmphista Therapeutics Appoints New Chairman, Joshua T. Brumm - PRNewswireSeptember 22, 2021 | prnewswire.comCidara Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer, and Shane Ward as Chief Legal Officer and Corporate Secretary - Yahoo FinanceSeptember 3, 2021 | finance.yahoo.comSee More Headlines VSAR Stock Analysis - Frequently Asked Questions How were Versartis' earnings last quarter? Versartis, Inc. (NASDAQ:VSAR) issued its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping analysts' consensus estimates of ($0.96) by $0.69. What other stocks do shareholders of Versartis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Versartis investors own include Progenics Pharmaceuticals (PGNX), ZIOPHARM Oncology (ZIOP), Bausch Health Companies (BHC), Flexion Therapeutics (FLXN), Genocea Biosciences (GNCA), Novavax (NVAX) and Protalix BioTherapeutics (PLX). Company Calendar Last Earnings8/07/2018Today5/24/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:VSAR CIK1513818 Webwww.versartis.com Phone(936) 355-1910FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:VSAR) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | SponsoredMemorial Day Sale! Save 85% on Weiss Crypto Investor!President Trump just made his first big crypto move … Announcing the creation of a national strategic reser...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Versartis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Versartis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VSAR Stock Free VSAR Stock Alerts